Our science & medical news
RSS feedGenoTher Summit 2025: Shaping the Future of Gene Therapy together
GenoTher Summit 2025, the first symposium organised by the GenoTher biocluster, was held on 11 June 2025 at the Génocentre in Évry-Courcouronnes. It brought together more than 350 key players in the gene therapy ecosystem for a day of scientific exchange and strategic reflection. More than 20 international experts from France, the United States, the … [Read more]
Exploring the infinitely small – Interview with Stéphane Vassilopoulos
An expert in cell biology and molecular biology, Stéphane Vassilopoulos is co-director of the ‘Muscle cell organization and therapy of dominant centronuclear myopathy‘ team at the Institute’s Center of Research in Myology. Seeking to understand why and how the alteration of certain muscle proteins leads to dysfunction and then disease, he and his team have … [Read more]
Seeing our muscles in action – Interview with Constantin Slioussarenko
Constantin Slioussarenko, an engineer by training, is a researcher in the NMR and Spectroscopy Laboratory, co-directed by Harmen Reyngoud and Benjamin Marty, at the Neuromuscular Investigation Center. The team works on neuromuscular diseases that affect all the muscles in the body, and whose progression can be fairly heterogeneous, making it difficult to monitor their progress … [Read more]
Building the Muscle Atlas – Interview with Bruno Cadot
Bruno Cadot is head of research in the ‘Signalling pathways and striated muscles’ team led by Antoine Muchir at the Center of Research in Myology . His work has led him to make extensive use of imaging to study muscle and to collaborate with the Institute’s Morphological unit*, which produces and studies sections of patient … [Read more]
A model to predict the distance covered during the 6MWT in Pompe disease
Researchers from the Laboratory of Physiology and Neuromuscular Evaluation at the Institute of Myology have developed and validated predictive models for the performance of the 6-minute walk test (6MWT) in Pompe disease, using simpler, less demanding tests. In fact, the 6MWT, which is commonly used to assess functional capacity in neuromuscular diseases, can prove difficult … [Read more]
The Institute’s teams at the 5th International Meeting on Laminopathies from 21 to 23 May in Paris
The 5th International Meeting on Laminopathies, being held in Paris from 21 to 23 May, brings together international experts in nuclear envelope proteins and associated diseases, including muscular dystrophies, cardiomyopathies, accelerated ageing syndromes such as Hutchinson-Gilford progeria and metabolic disorders. This meeting, which gathers together cardiologists, neurologists, endocrinologists, paediatricians, geneticists, researchers and patients, aims to … [Read more]
Researchers from the Institute at the 15th MGFA International Conference
Institute researchers at the 15th International MGFA ConferenceInstitute experts presented their work at the 15th International MGFA Conference on myasthenia gravis and associated disorders, held from 13 May to 15 May 2025 in The Hague, Netherlands. Organised by the Myasthenia Gravis Foundation of America (MGFA), this conference brings together neuromuscular researchers and healthcare professionals to … [Read more]
A new murine model of myasthenia gravis that is more effective and better suited to animal welfare
The Myasthenia gravis, etiology, pathophysiology & therapeutical approaches team, led by Rozen Le Panse at the Institute of Myology’s Myology Research Centre, has developed a new experimental murine model of myasthenia gravis (N-EAMG) that is at least as effective as the classic experimental model (C-EAMG) and offers several advantages. N-EAMG: is better suited to animal … [Read more]
Identification of effective, non-invasive MRI markers in LGMD R9
French researchers from the Institute of Myology, Genethon and Atamyo, in collaboration with Dutch researchers, have studied several quantitative MRI parameters in order to identify sensitive and non-invasive biomarkers for assessing the progression of LGMD-R9 and evaluating the efficacy of new therapies. Carried out in 18 persons with LGMD-R9 and 13 controls, this study shows … [Read more]
The benefit of reusing data from placebo groups in inclusion myositis
American researchers associated with the Institute of Myology Research Centre have compiled and re-analysed the data accumulated in the placebo arms of several clinical trials in inclusion myositis (IMM) : 11 therapeutic trials were selected, they involved 257 participants who had received only a placebo, the main endpoints were changes in muscle strength and, in … [Read more]
